Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Razieh Kebriaei; Katherine L Lev; Kyle C Stamper; Susan M Lehman; Sandra Morales; Michael J Rybak

doi:10.1128/AAC.01863-20

Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01863-20. doi: 10.1128/AAC.01863-20. Print 2020 Dec 16.

Authors

Razieh Kebriaei¹, Katherine L Lev¹, Kyle C Stamper¹, Susan M Lehman², Sandra Morales², Michael J Rybak^{3

4

5}

Affiliations

¹ Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
² AmpliPhi Biosciences Corporation, San Diego, California, USA.
³ Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA m.rybak@wayne.edu.
⁴ School of Medicine, Wayne State University, Detroit, Michigan, USA.
⁵ Detroit Receiving and University Health Center, Detroit, Michigan, USA.

Abstract

This study aimed to test the efficacy of bacteriophage-antibiotic combinations (BACs) in vitro in 24-h time-kill settings and in ex vivo simulated endocardial vegetation (SEV) pharmacokinetic/pharmacodynamic models for 96 h. BACs prevented the development of bacteriophage resistance, while some bacteriophage resistance emerged in bacteriophage-alone treatments. In addition, BACs resulted in an enhancement of bacterial eradication in SEV models. Our findings support the potential activity of BAC therapy for combating serious methicillin-resistant Staphylococcus aureus (MRSA) infections.

Keywords: bacteriophage; combination; infective endocarditis.

MeSH terms

Anti-Bacterial Agents / pharmacology
Bacteriophages*
Humans
Methicillin-Resistant Staphylococcus aureus*
Microbial Sensitivity Tests
Staphylococcal Infections* / drug therapy

Substances

Anti-Bacterial Agents